

Edgar Filing: MESA LABORATORIES INC /CO - Form SC 13D

MESA LABORATORIES INC /CO
Form SC 13D
March 04, 2005

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 13D
(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13d-2(a)
(Amendment No.) (1)

Mesa Laboratories, Inc.

(Name of Issuer)

Common Stock, no par value

(Title of Class of Securities)

59064R 10 9

(CUSIP Number)

Farnam Street Partners, L.P.
Farnam Street Capital, Inc.
3033 Excelsior Boulevard, Suite 300
Minneapolis, MN 55416
Phone: (612) 253-6058

With a copy to:
Douglas T. Holod, Esq.
Maslon Edelman Borman & Brand, LLP
3300 Wells Fargo Center
90 South Seventh Street
Minneapolis, MN 55402-4140
Phone: (612) 672-8200

(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)

February 24, 2005

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [].

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

Edgar Filing: MESA LABORATORIES INC /CO - Form SC 13D

(1) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 59064R 10 9

Page 2 of 8

1 NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
(ENTITIES ONLY)

Farnam Street Partners, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(See Instructions)

(a)
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions)

00 (Investment proceeds)

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) OR 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Minnesota

7 SOLE VOTING POWER

NUMBER OF

118,514

SHARES

BENEFICIALLY

8 SHARED VOTING POWER

0

OWNED BY EACH

9 SOLE DISPOSITIVE POWER

REPORTING

118,514

PERSON

10 SHARED DISPOSITIVE POWER

WITH

Edgar Filing: MESA LABORATORIES INC /CO - Form SC 13D

0

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
118,514

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES (See Instructions) []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
3.9%

14 TYPE OF REPORTING PERSON (See Instructions)
PN

CUSIP No. 59064R 10 9

Page 3 of 8

1 NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
(ENTITIES ONLY)

Farnam Street Capital, Inc.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(See Instructions)

(a) []
(b) []

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions)

00 (Investment proceeds)

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) OR 2(e)
[]

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Minnesota

7 SOLE VOTING POWER
NUMBER OF 174,234 (See Explanation in Item 5)
SHARES

8 SHARED VOTING POWER
BENEFICIALLY 0

9 SOLE DISPOSITIVE POWER
OWNED BY EACH

Edgar Filing: MESA LABORATORIES INC /CO - Form SC 13D

REPORTING

174,234 (See Explanation in Item 5)

PERSON

10 SHARED DISPOSITIVE POWER

WITH

0

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
174,234 (See Explanation in Item 5)

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES (See Instructions) []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

5.7% (See Explanation in Item 5)

14 TYPE OF REPORTING PERSON (See Instructions)

PN

CUSIP No. 59064R 10 9

Page 4 of 8

1 NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
(ENTITIES ONLY)

Raymond E. Cabillot

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(See Instructions)

(a) []

(b) []

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions)

None

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) OR 2(e)

[]

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Minnesota

NUMBER OF 7 SOLE VOTING POWER

0

SHARES

8 SHARED VOTING POWER

Edgar Filing: MESA LABORATORIES INC /CO - Form SC 13D

BENEFICIALLY
174,234
OWNED BY EACH -----
9 SOLE DISPOSITIVE POWER
REPORTING
0
PERSON -----
10 SHARED DISPOSITIVE POWER
WITH
174,234

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
174,234 (See Item 5(b))

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES (See Instructions) []

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
5.7%

14 TYPE OF REPORTING PERSON (See Instructions)
IN

CUSIP No. 59064R 10 9 Page 5 of 8

1 NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
(ENTITIES ONLY)
Peter O. Haeg

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(See Instructions)
(a) []
(b) []

3 SEC USE ONLY

4 SOURCE OF FUNDS (See Instructions)
None

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) OR 2(e)
[]

6 CITIZENSHIP OR PLACE OF ORGANIZATION
Minnesota

7 SOLE VOTING POWER

Edgar Filing: MESA LABORATORIES INC /CO - Form SC 13D

NUMBER OF	0	
SHARES	-----	
	8	SHARED VOTING POWER
BENEFICIALLY	174,234	
OWNED BY EACH	-----	
REPORTING	9	SOLE DISPOSITIVE POWER
PERSON	0	
WITH	-----	
	10	SHARED DISPOSITIVE POWER
	174,234	

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	174,234 (See Item 5(b))	

12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)	[]

13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)	
	5.7%	

14	TYPE OF REPORTING PERSON (See Instructions)	
	IN	

ITEM 1. SECURITY AND ISSUER

This statement relates to the common stock, no par value, of Mesa Laboratories, Inc., a Colorado corporation ("Winmark" or the "Company" or the "Issuer"). The address of the Company's principal executive offices is 12100 West Sixth Avenue, Lakewood, CO 80228.

ITEM 2. IDENTITY AND BACKGROUND

(a) This Schedule 13D is being filed by Farnam Street Partners, L.P., a Minnesota Limited Partnership (the "Fund"), and by its General Partner, Farnam Street Capital, Inc., a Minnesota corporation ("FSC"). Mr. Raymond E. Cabillot is Chief Executive Officer and Chief Financial Officer and Mr. Peter O. Haeg is President and Secretary of FSC. The Fund and FSC are making this filing because they are the beneficial owner, pursuant to Rule 13d-3 under the Securities Exchange Act of 1934 (the "Exchange Act"), of more than five percent (5%) of the outstanding shares of Common Stock of the Issuer.

(b) The principal office of the Fund, FSC and Messrs. Cabillot and Haeg is 3033 Excelsior Boulevard, Suite 300, Minneapolis, Minnesota 55416.

(c) The Fund was organized in January 1998 as a Minnesota Limited Partnership. FSC is a Minnesota corporation. Its principal business activities involve investing in equity securities of publicly traded companies, as well as other types of securities.

(d) - (e) During the last five years, neither the Fund, FSC nor the

Edgar Filing: MESA LABORATORIES INC /CO - Form SC 13D

principals of its General Partner have been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) nor have the parties been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such individual was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting, or mandating activity subject to, federal or state securities laws or finding any violation with respect to such laws.

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

The aggregate purchase price of the purchases identified in response to Item 5(c) was \$584,250.16. All such purchases were paid for with investment proceeds from various limited partnership interests. All securities identified in response to Item 5(c) were acquired by open market purchases.

ITEM 4. PURPOSE OF TRANSACTION

All of the shares of the Company owned by the Reporting Person were, at the time of their purchase, acquired for investment purposes in the ordinary course of business. FSC makes investments in companies that it believes are undervalued and represent an attractive investment opportunity. FSC may from time to time purchase additional shares of the Company's stock or dispose of all or some of the shares.

Except as set forth in this Item 4, FSC has no present plans or proposal that relates to or would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D. FSC intends to review its investment in the Issuer on a continuing basis and, depending on various factors, including, without limitation, the Issuer's financial position and investment strategy, the price levels of the common stock, conditions in the securities markets, conditions in the industry and general economic conditions, may in the future take such actions with respect to its investment in the Issuer as it deems appropriate including, without limitation, purchasing additional shares of common stock or selling some or all of its shares or to change its intention with respect to any and all matters to in Item 4.

ITEM 5. INTEREST IN THE SECURITIES OF THE ISSUER

(a) FSC manages the Fund and a separate account which together beneficially own 174,234 shares of common stock of the Issuer, representing 5.7% of the shares outstanding. The Fund beneficially owns 118,514 shares of the outstanding Common Stock of the Issuer, representing approximately 3.9% of the Common Stock (based upon 3,045,527 shares outstanding on December 31, 2004, as reported in the Issuer's most recent 10-Q filed on February 14, 2005).

(b) The Fund does not share voting and dispositive power with respect to any shares. However, Messrs. Cabillot and Haeg, as officers of FSC, may be deemed to have beneficial ownership of the shares reported in this Schedule 13D by virtue of their shared voting and dispositive power. However, they disclaim beneficial ownership and have no direct pecuniary interest in the shares.

(c) TRANSACTIONS WITHIN THE LAST 60 DAYS OR SINCE THE LAST FILING.

The following purchases took place within the last 60 days:

No. of	Price per
--------	-----------

Edgar Filing: MESA LABORATORIES INC /CO - Form SC 13D

Trade Date	Shares	share
1/13/2005	850	\$11.7953
1/20/2005	800	\$12.1463
2/3/2005	500	\$12.1500
2/7/2005	2,300	\$12.0904
2/8/2005	1,100	\$12.1200
2/9/2005	500	\$12.1500
2/11/2005	3,600	\$12.5393
2/14/2005	800	\$12.6000
2/16/2005	4,000	\$12.5508
2/17/2005	2,000	\$12.4100
2/22/2005	4,200	\$12.2314
2/23/2005	3,000	\$12.2333
2/24/2005	19,300	\$12.0340
2/25/2005	3,200	\$12.3611
3/1/2005	1,000	\$12.3290
3/2/2005	700	\$12.5143

The following sale took place in the last 60 days:

Trade Date	No. of Shares	Price per share
1/25/2005	1,000	\$13.0500

(d) Not applicable.

(e) Not applicable.

ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS WITH RESPECT TO SECURITIES OF THE ISSUER

There are no contracts, arrangements, understandings or relationships between the Fund or FSC, on one hand, and any other person with respect to any securities of the Issuer on the other hand.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

None

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.

Dated: March 3, 2005

FARNAM STREET PARTNERS, L.P.
 BY: FARNAM STREET CAPITAL, INC.,
 General Partner

Edgar Filing: MESA LABORATORIES INC /CO - Form SC 13D

By: /s/ Raymond E. Cabillot

Raymond E. Cabillot,
Chief Executive Officer

By: /s/ Peter O. Haeg

Peter O. Haeg,
President

/s/ Raymond E. Cabillot

RAYMOND E. CABILLOT

/s/ Peter O. Haeg

PETER O. HAEG